4D Molecular Therapeutics, Inc. (FDMT) is a clinical-stage genetic-medicines company, not an ETF. Reviewing seven recent, named price targets — B. Riley Securities at $37, H.C. Wainwright at $36, RBC Capital at $35, Bank of America Securities at $33, Barclays at $28, Chardan Capital at $25, and Cantor Fitzgerald at $20 — yields an arithmetic mean of about $30.57, rounded here to $31. The range is unusually wide, roughly $20 to $37, a sign of genuine disagreement rather than a tight consensus. Broader aggregators report similar figures: StockAnalysis lists an average near $28 with 12 analysts, while MarketBeat shows about $30 across 11, so the $31 target sits comfortably within published consensus estimates.
Ratings skew bullish, with most firms at Buy, Outperform, or Overweight. Morgan Stanley maintains a Hold without a price target, and Cantor Fitzgerald upgraded the stock to Overweight in September 2026. Bullish analysts emphasize 4D-150's differentiated, potentially durable treatment profile; more cautious targets reflect clinical, regulatory, and financing uncertainty.
Shares closed near $12.48 in early November 2026, giving the company a market capitalization of roughly $690 million. Reaching $31 implies upside of about 148%, a very large move that would exceed the stock's 52-week high of $16.93 by a wide margin. That path almost certainly depends on positive Phase 3 data for 4D-150 in wet AMD, where the 4FRONT program has completed enrollment early in its second pivotal trial, with key readouts expected in 2027. Between now and then, the shares are likely to trade more on data milestones and financing headlines than on quarterly financials, given that the company is not yet profitable.
The core thesis is 4D-150, an intravitreal gene therapy designed to reduce the injection burden of standard anti-VEGF treatments in wet AMD and diabetic macular edema. Encouraging Phase 2 durability data and efficient Phase 3 enrollment support the bull case. The balance sheet is also a strength: roughly $361 million in cash and a net cash position near $391 million (about $7 per share), supplemented by a credit facility, is expected to fund operations into the second half of 2028. A favorable data readout, further positive analyst revisions, or a partnership could all compress the wide valuation gap between the current price and the target.
The risks are substantial. The company posts meaningful losses — consensus forecasts roughly a $4.15 per-share loss for 2026 — with revenue that is milestone-dependent and highly variable. Gene-therapy trials carry binary risk, and 4D-150 must compete against established anti-VEGF therapies and other emerging approaches. Financing and dilution remain live concerns, while short interest of roughly 21% of shares outstanding and roughly $1.66 million in recent insider selling add to the overhang. A disappointing data readout could sharply re-rate the shares, making the target much harder to justify.
The stock trades between its 200-day moving average near $11 and its 50-day average near $13.35, suggesting a broad consolidation after a volatile 12 months. Key support sits around the $11.00–$10.80 zone, while resistance is layered near $13.50 and again at the 52-week high of $16.93. A decisive break above that high would be required before the $31 target even becomes a realistic technical consideration.
Analyst price targets generally reflect a roughly 12-month research horizon, though the 4D-150 data catalysts stretch into 2027, so individual assumptions differ materially. Investors should watch the upcoming quarterly report, enrollment and data timelines for the 4FRONT program, any financing or partnership announcements, changes in analyst targets and ratings, and shifts in short interest. Biotech-sector risk appetite and interest-rate dynamics also matter for this high-beta name.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like FDMT, this kind of automated scanning can help traders surface opportunities, monitor existing positions, and identify changing trends more efficiently than manual chart review. Explore the signals to see how the system is reading current conditions.
Can FDMT reach $31? The target, an average of seven current analyst price targets, sits about 148% above the latest price — a very large move that hinges almost entirely on the clinical and commercial success of 4D-150. Strong cash reserves, early Phase 3 enrollment, and a bullish analyst tilt support the ambition, but persistent losses, binary data risk, high short interest, and a wide $20-to-$37 target range underscore the uncertainty. The next data readouts and financing decisions, not near-term earnings, are likely to determine whether the gap toward $31 can narrow.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, FDMT has been loosely correlated with KYTX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if FDMT jumps, then KYTX could also see price increases.
| Ticker / NAME | Correlation To FDMT | 1D Price Change % | ||
|---|---|---|---|---|
| FDMT | 100% | +4.25% | ||
| KYTX - FDMT | 59% Loosely correlated | +0.79% | ||
| PRME - FDMT | 55% Loosely correlated | +10.26% | ||
| RCKT - FDMT | 55% Loosely correlated | +1.22% | ||
| EDIT - FDMT | 54% Loosely correlated | -4.99% | ||
| SLDB - FDMT | 54% Loosely correlated | +6.00% | ||
More | ||||